CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it will collaborate with the National Cancer Institute to test the anti-cancer impact of Sirtris’ SIRT1 enzyme activators in numerous models of cancer.
